Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Tr… (NCT06199232) | Clinical Trial Compass
Active — Not RecruitingNot Applicable
Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment
China47 participantsStarted 2024-01-23
Plain-language summary
Hepatic arterial infuison chemothearpy (HAIC), targeted therapy, and programmed death-1 (PD-1) inhibitors have been demonstrated to be effective for colorectal cancer liver metastasis (CRCLM). Thus, the investigators will conduct a prospective trial to explore the efficacy and safety of targeted treatment based on ctDNA genotyping combined with tislelizumab and HAIC as salvage treatment for advanced CRCLM failed from standard systemic treatment, aiming to provide individualized optimized regimen for microsatellite stable (MSS) CRCLM in salvage treatment.
Who can participate
Age range18 Years – 80 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. 18-80 years old.
✓. Colorectal cancer confirmed by histopatology.
✓. The metastasis is mainly located in liver.
✓. Unresectable liver metastasis is confirmed by CT/MRI scan and multidisciplinary.
✓. Failed from standard first- and second-line systemic treatment.
✓. At least one measurable lesion according to modified Response Evaluation Criteria in Solid Tumors guidelines (mRECIST).
✓. Eastern Cooperative Oncology Group (ECOG) performance status \<2.
✓. Child-Pugh A or B (≤ 7).
Exclusion criteria
✕. Extensive extrahepatic metastasis (\>25% of tumor burden in liver).
✕. HER2 (3+) or HER2 amplification.
✕
What they're measuring
1
PFS rate at 6 months
Timeframe: From the date of treatment begining to the date of 6 months after the treatment begining.